BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics.
- Products & Solutions
- FDA IVD
- About Us
- News & Events
- Contact
- Additional Sites
Category: News
BÜHLMANN fCAL® ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, which presents with periods of inflammatory activity (flares) and quiescent phases (remission) as can be seen in many chronic diseases. IBD includes several different diseases; the two most important
Continue Reading
An outstanding research paper was published in the top rated Journal of Allergen and Clinical Immunology which evaluated the performance of basophil activation as a biomarker in monitoring clinical efficacy of oral peanut immunotherapy in a clinical trial.
BÜHLMANN fCAL® turbo + CALEX® Cap (K191718): FDA 510(k) cleared. For in vitro Diagnostic Use. Health Canada License: 98839 CALEX® Cap CALEX® Cap is an FDA 510(k) cleared fecal extraction device for use with BÜHLMANN fCAL® turbo that provides excellent correlation to the traditional manual weighing method and offers efficient, convenient and hygienic extraction of stool samples. Its unique design
Continue Reading
Flow CAST®: Research Use Only in the US. Not for diagnostic procedures. Health Canada License:101781 BÜHLMANN Flow CAST® and Basophil Activation (BAT): Basophil Activation Tests (BAT) have been extensively studied as in vitro functional assays and have demonstrated superior accuracy as compared to other blood tests for various allergies (1). BÜHLMANN provides a broad range of
Continue Reading
IBDoc® Publications View a compilation of BÜHLMANN IBDoc® calprotectin citations from a wide variety of interesting publications, studies, and posters. Find valuable highlights from each publication and see the long list of studies that have utilized our assay! View Citations Health Canada License: 98903 US: Not available for Sale in the US.
Continue Reading
BÜHLMANN launched its first fecal calprotectin assay over 10 years ago and since then has developed into THE CALPROTECTIN COMPANY with the highest quality standards. The offerings include the FDA 510(k) cleared BÜHLMANN fCAL® ELISA, the FDA 510(k) cleared automated BÜHLMANN fCAL® turbo (in combination with CALEX® Cap fecal extraction device) for testing on most
Continue Reading
IBDoc® IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. Based on BÜHLMANN’s long-lasting experience with calprotectin assays, IBDoc® provides IBD patients a convenient method for self-testing. CALEX® Valve has been developed for simple and easy-to-handle stool extraction with a valve designed to allow the precise application
Continue Reading
BÜHLMANN Educational Workshop at EuroMedLab 2019 The BÜHLMANN Educational Workshop at EuroMedLab 2019, focused on optimizing workflow for fecal calprotectin testing was a great success. This workshop offered insightful presentations from three laboratories discussing the process of stool sample pre-analytics and how they worked to find a solution to cope with continuously increasing test numbers.
Continue Reading
Meeting of the Minds 2019 BUHLMANN Diagnostics Corp Stop by our Booth! Nov 15-16, 2019 | Ritz Carlton Hotel | Toronto, ON Event Info: https://crohnsandcolitis.ca/meetingoftheminds Visit our booth to get an update on our IBDoc® Calprotectin Home Test: IBDoc®, the in-vitro diagnostic POC and home testing device to measure the inflammatory marker, fecal calprotectin Learn More Click & Contact Meeting of the Minds
Continue Reading
